NCT07461675 2026-03-10
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
University of Geneva, Switzerland
Phase 3 Not yet recruiting
Clinical Trials
20 trialsNCT04777851 2026-03-09
REPLACE
Translational Research in Oncology
Phase 3 Terminated
NCT03847428 2026-03-06
EMERALD-2
AstraZeneca
Phase 3 Active not recruiting
NCT04039607 2026-02-19
CheckMate 9DW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT07417397 2026-02-18
Adjuvant TACE in HCC With High-risk Recurrence Factors
Guangxi Medical University
Phase 3 Recruiting
NCT03186898 2026-02-13
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NRG Oncology
Phase 3 Active not recruiting
NCT03713593 2026-02-05
LEAP-002
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03867084 2026-02-04
KEYNOTE-937
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07381660 2026-02-02
SBRT Versus Surgical Resection for Small HCC
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT04712643 2026-01-30
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT01730937 2026-01-28
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT05198609 2026-01-21
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
Sun Yat-sen University
Phase 3 Active not recruiting
NCT07356037 2026-01-21
Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT03778957 2026-01-16
EMERALD-1
AstraZeneca
Phase 3 Active not recruiting
NCT03298451 2026-01-14
HIMALAYA
AstraZeneca
Phase 3 Active not recruiting
NCT06921785 2026-01-09
ARTEMIDE-HCC01
AstraZeneca
Phase 3 Recruiting
NCT03654053 2026-01-07
SACRED
VA Office of Research and Development
Phase 3 Active not recruiting
NCT07322848 2026-01-07
UPGRADE
First Affiliated Hospital, Sun Yat-Sen University
Phase 3 Recruiting
NCT05904886 2025-12-31
SKYSCRAPER-14
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04639180 2025-12-30
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting